Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BeiGene, Hengrui Among China Firms Flexing New Oncology Muscle At ASCO

Executive Summary

In its bid to facilitate novel treatments for some of its most prevalent cancers, China is also poised to make a dent in the global oncology market through domestically originated agents, with the number of PD-1 and CAR-T therapies under clinical development already surpassing that in the US.

You may also be interested in...



Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate

BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.

Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.

Fifth PD-1, Zavicefta, Novel Psoriasis Ointment Among Latest China Approvals

Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125346

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel